GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo

GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo

GZD824 is a novel third-generation BCR-ABL inhibitor. It entered Phase II clinical trials in China and Phase Ib clinical trials in USA in 2019 for treatment of patients with resistant chronic myeloid leukemia (CML). We found that at concentrations below 10 nM, GZD824 significantly suppresses FLT3, F...

Full description

Bibliographic Details
Main Authors: Yuting Wang, Lenghe Zhang, Xia Tang, Jinfeng Luo, Zhengchao Tu, Kaili Jiang, Xiaomei Ren, Fang Xu, Shingpan Chan, Yuhua Li, Zhang Zhang, Ke Ding
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319307612

Similar Items

Similar Items